We circle back to allogenic (off-the-shelf) cell therapy concern Caribou Biosciences for the first time since last Spring. Caribou is advancing three early-stage candidates within its pipeline, and ...
Shares of Caribou Biosciences (NASDAQ:CRBU) will be in focus on Friday after the gene-editing biotech announced plans to prioritize its lead oncology clinical programs, CB-010 and CB-011, as part of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results